Global drugmakers said they could cut research spending in Japan due to new rules requiring them to slash prices on some blockbuster drugs, including Gilead Sciences Inc’s highly effective but expensive hepatitis C drug, Sovaldi. Drugmakers such as the Japanese arms of Pfizer Inc and Eli Lilly and Co said the change, which could as […]
For breast cancer survivors, the risk of recurrence may be tied to how many hours they fast at night, a new study suggests.
Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics Pivotal RA-BEACON Study Published in New England Journal of Medicine 07:00 ET from Eli Lilly and Company; Incyte Corporation INDIANAPOLIS, March 31, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) […]
Billionaire Michael Bloomberg and other philanthropists are donating $125 million to Johns Hopkins University for a new institute devoted to immunotherapy cancer research, the Baltimore school said on Tuesday. Bloomberg, founder of the business and market news firm bearing his name and a former New York City mayor, and Sidney Kimmel, founder of Jones Apparel […]
Keryx Biopharmaceuticals Inc. said its drug to treat iron deficiency anemia in chronic kidney disease patients not yet requiring dialysis met the goals of a late-stage clinical trial.
Alder BioPharmaceuticals Inc. said its injection to prevent migraines had met the main goal in a mid-stage study.
There’s a slightly hollow feeling about the faded business park which was once home to Pfizer’s bustling R&D community and supported thousands of jobs in the nearby town of Sandwich.
While every medical case is unique, payers and providers are attempting to standardize treatment since unnecessary variation is a major source of growing costs.
The analysts at Thomson Reuters have consulted their crystal balls and come up with seven drugs coming out this year that will likely hit blockbuster status – defined as marking more than $1 billion annually.
March 25, 2016 By Mark Terry, BioSpace.com Breaking News Staff Waltham, Mass.-based FORUM Pharmaceuticals, in light of two Phase III trial disappointments, is laying off half its staff and restructuring the company. In September 2015, the U.S. Food and Drug Administration (FDA) advised FORUM to halt its clinical trials of encenicline for Alzheimer’s disease. […]